Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 13, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transaction details.
- Share Price: GBP 12.74 per Ordinary Share.
- Transaction Type: Re-investment of dividends paid on July 12, 2007.
Material Changes
The filing details an increase in share interests for the following individuals following the dividend re-investment:
- Mr J S Heslop: 290 shares
- Mrs P A Heslop: 70 shares
- Mr R Bondy: 315 shares
- Mr D Learmouth: 46 shares
- Dr D Pulman: 131 shares
- Mr A P Witty: 21 shares
- Mrs C M Witty: 289 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to disclosure rules regarding director transactions.
Key Facts for Investor Verification
- Verify the total number of shares held by the named directors prior to this transaction to assess total ownership concentration.
- Confirm the dividend amount per share paid on July 12, 2007, to validate the re-investment calculation.
- Check subsequent filings to ensure all required disclosures under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) were completed.